Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, polymorphisms of the IGF-1 promoter may have been introduced during the genesis of EC and contributed to it by leading to aberrant expression of IGF-1.
|
27121258 |
2016 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IR-A/IGF-1R-mediated signals promote epithelial-mesenchymal transition of endometrial carcinoma cells by activating PI3K/AKT and ERK pathways.
|
30426831 |
2019 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through a series of experiments, the insulin‑like growth factor receptor 1 (IGF‑1R) was identified as a novel direct target of miR‑381 in EC.
|
29257334 |
2018 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been shown that: (i) high serum concentrations of IGF-1 and IGF-2 are associated with an increased risk of breast, prostate, colorectal and lung cancers; and (ii) IGF-R1 is commonly disturbed in many tumours (like gastric, lung, endometrial cancer) leading to a phenotype of anchorage-independent tumour growth.
|
17598937 |
2007 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate a reduced expression of IGF-I mRNA in endometrial carcinomas compared with non-neoplastic tissues, despite equivalent immunohistochemical expression of IGF-I and IGF-I receptor.
|
9935198 |
1999 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, metformin can reduce the secretion of IGF-1 by Ishikawa and JEC EC cell lines and their expression of IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth.
|
25640355 |
2015 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The profiles of IGF-I and II transcripts of endometrium from Tam-treated patients were similar to Type I EC but differed considerably from those of Type II EC.
|
10940495 |
2000 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E.
|
18852162 |
2009 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, IGF-IR was mostly overexpressed in type I endometrial cancer.
|
31168597 |
2019 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results showed that RNAi mediated down-regulation of IGF-1R expression in endometrial carcinoma significantly induced apoptosis, reduced downstream protein phosphorylation and decreased tumorigenicity in vivo accompanied with lower proliferation index in tumor tissue, Which implied the therapeutic potential of RNAi in the treatment of endometrial carcinoma by targeting IGF-1R and IGF-1R may be a potential therapeutic target for human endometrial carcinoma.
|
21145998 |
2011 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we have examined the effects of 17-beta estradiol (E2) on expression and synthesis of insulin-like growth factors (IGF-I and IGF-II) and the insulin-like growth factor binding proteins (IGFBPs) by Ishikawa human endometrial cancer cells.
|
7527333 |
1994 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The insulin-like growth factor (IGF) system is related to EC risk, and IGF-I can inhibit PR transcription in breast cancer.
|
21168492 |
2011 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.
|
26193427 |
2015 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The IGF-IR mRNA was overexpressed in all endometrial cancers including the carcinosarcoma sample, but not in normal endometrium.
|
10779632 |
2000 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Positive relationships between IGF-I expression and two classic forms of NF-κB p50 and p65 in endometrial cancer were revealed.
|
22711307 |
2012 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A higher risk for cervical, ovarian and endometrial cancer is related to high IGF-1 levels in post- and premenopausal women.
|
11955796 |
2002 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further work is needed to establish if IGF-1 plays a role in a subset of endometrial cancers and if isoforms of VEGF play a role in endometrial cancer.
|
15917160 |
2005 |
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, we did not observe any statistically significant associations with the polymorphisms in IGFI and IGFBP1 and endometrial cancer risk.
|
21078522 |
2011 |
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, the IGF-I and II mRNA levels were conspicuously low in many carcinoma samples, which were not associated with hyperplasia (type II EC), but relatively elevated in two other carcinoma samples, associated with adenomatous hyperplasia (type I EC).
|
10459850 |
1999 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGFs (IGF-I and IGF-II) are also potent mitogens in endometrial cancer.
|
7523316 |
1994 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lentivirus-mediated shRNA targeting IGF-1R has the potential to develop as a clinical treatment method in advanced and chemoresistant endometrial carcinoma.
|
21442237 |
2011 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that a KD would improve body composition and lower serum insulin and insulin-like growth factor-I (IGF-I) in women with ovarian or endometrial cancer.
|
30137481 |
2018 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer.
|
31320996 |
2019 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated the potential ability of MK-0646 to inhibit IGF1-mediated biological actions and cell signaling events in Type 1 and Type 2 endometrial cancer.
|
23402816 |
2013 |
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol.
|
7750475 |
1995 |